MabVax Holdings

MabVax Therapeutics was a clinical-stage biotechnology company specializing in the development of proprietary human monoclonal antibody products and vaccines for the treatment of various cancers. The company's primary focus was on targeting the Sialyl Lewis A (sLea) antigen, a carbohydrate structure frequently overexpressed on the surface of solid tumor cells, including pancreatic and colon cancers. Their lead therapeutic candidate, MVT-5873, was a fully human monoclonal antibody that served as a standalone therapy and a targeting shell for their radioimmunotherapy and imaging programs. Despite promising early-stage clinical data, the company faced significant financial challenges and filed for Chapter 11 bankruptcy in 2019. Subsequently, its core antibody assets and intellectual property were acquired by BioNTech to bolster their oncology pipeline.